Posted on

Wuhan General Group Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited

CAPE TOWN, SA / ACCESSWIRE / July 17, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective July 16th, 2020, it has signed a Memorandum of Agreement to pursue the Acquisition (the “Transaction”) of Tsime Pharmaceuticals and Medicinal Supplies (Pty) Ltd (“Tsime”). Tsime will become a subsidiary of MJ Medtech. The Tsime license grants the ability to cultivate, extract and process medicinal cannabis and sell the commodity for medicinal, scientific and any other legal purpose. The Transaction is anticipated to close within 90 days.

Located in the Kingdom of Lesotho in Southern Africa, Tsime has the license for the cultivation of 3 hectares of medicinal grade cannabis on a farm with a land area covering 32 hectares or 80 acres.

The acquisition is extremely strategic for Wuhan. Having its own cultivation, extraction and processing medicinal cannabis operation, is key to driving research and the manufacturing of CBD by-products.

Lesotho offers remarkable advantages:

  • Climate: Lesotho has ideal climate conditions for cannabis plant cultivation.
  • Groundwater availability and soil quality: Excellent economic growing conditions.
  • Abundant land: Mountainous hectares allows for large, open-air crops.
  • Elevation and protection: Average elevation of Lesotho is 2255 meters or 7,090 feet.
  • Labour: Low cost experienced growers and readily available local workforce.
  • Government: Pro cannabis with a low regulatory burden.

Willem Jonker, speaking on behalf of the Medigrow Africa Group, said: ” M2Bio Sciences already sources top-quality coffee from Tanzania, and will now be able to control the production of top-quality cannabis from Lesotho for their product range. The world will be impressed by the results. ”

“Cannabis cultivation was off our radar and low on the priority list until recently. The big and much-needed shakeout in the cannabis sector has offered up tremendous opportunities for Wuhan and its shareholders. As many companies have been forced to leave the battlefield badly wounded, some mortally, we enter the arena unscathed and at a fraction of the costs. We plan to expand our relationship considerably in the coming months with Willem and Medigrow Africa. Furthermore, we are very proud to contribute to the economic development of Lesotho through this Transaction. The grass is greener in Africa! “ said Jeff Robinson, Chief Executive Officer of Wuhan General Group.

A summary of the transaction and timeline for production ramp-up will be made available after the closing of the Transaction.

About Medigrow Africa

Medigrow Africa is a formal network of legal African cannabis growers producing international-grade medical cannabis products for global distribution. Medigrow Africa is the largest collective of African cannabis businesses and it dominates the African medicinal cannabis industry. Medigrow benefits from lower labour, land, and regulatory costs. Also, Medigrow is in the lower quartile of production costs and the upper quartile of profitability globally.

https://www.medigrowafrica.com/

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
E-mail:info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/597842/Wuhan-General-Group-Signs-MOA-for-the-Acquisition-of-Tsime-Pharmaceuticals-PTY-Limited

Posted on

Wuhan General Group Signs Collaborative Partnership LOI With Jugular for CBD Functional Foods

MONTREAL, QC / ACCESSWIRE / July 1, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 30th, 2020, it has signed a letter of intent to pursue a Partnership where Jugular will support and offer its expertise to the Company in creating a specialized division within MJ Medtech that focuses on marketable innovation within the functional foods sector.

Functional Food is defined as any modified food that claims to improve health or well-being by providing benefits beyond that of the traditional nutrients it contains.

It is anticipated that the letter of intent will be replaced with a formal agreement governing the Partnership on or before September 30, 2020. The Parties will define their collaboration for the development and manufacturing of CBD Functional Foods immediately under the Dr. AnnaRx brand:

Immune Booster Shot: The pandemic has caused a significantly heightened awareness for immune-boosting supplements that are easily ingested. Special African medicinal roots and herbs are used in combination to create this very powerful immune booster tonic.

Energy Booster Shot: Quick energy on the go. The ultimate coffee powered CBD infused shot to get added energy into your system and amplify mental clarity quickly and effectively.

Relax and Unwind Shot: This powerful formulation of Rooibos, CBD, and 8 other African medicinal herbs will help relieve many of the tensions built up during the day enabling you to enjoy a most peaceful sleep.

“Jack and I have spent immeasurable hours over the past few years discussing food science and how we might see a fit in bringing the brains behind our organizations together. We are thrilled to make this a reality and to be working with a group that cares as much about the science as we do” said Jeff Robinson, Chief Executive Officer of Wuhan General Group.

Jack Napier, Jugular Director added: “Jeff and his team at M2BIO are putting everything in place to create the right moment to bring cannabinoid-based nutraceuticals to the mass market. Jugular in partnership with M2BIO will use its extensive experience in the functional foods retail sector to unlock a new area of global profitability in the fast-growing wellness industry. We are thrilled to begin this partnership as we see the enormous potential of creating marketable innovations in this untapped new field within functional nutrition.”

About Jugular

Jugular is an innovation partner within the wellness sector, implementing our skills to bring new functional food & nutraceutical products from concept to market. Jugular comprises a cross-specialized team of wellness professionals and scientists that are passionate about making a positive impact on the world by advocating a healthy lifestyle through innovative products that are good for you. We own multiple functional food brands that are sold throughout Europe and distributed Internationally.

??Our Vision

?We seek to develop groundbreaking products incorporating new & novel ingredients into the wellness sector.

?Our Mission

?To help as many people as possible get access to advanced nutritional products. To educate, inform and break down the stigma surrounding novel foods.

?Our Strategy

?Jugular brings cutting edge new products from the concept phase through the critical path to launch. We provide expertise in sourcing, designing, manufacturing, logistics & marketing over a broad array of products including:

  • Functional Foods & RTE (Ready to Eat)
  • Ready to Drink shots and bottles
  • Powder supplements
  • Capsules, softgel and hard form nutraceuticals

We help producers and innovators of new novel ingredients find their way to the mainstream & the profitability that comes with it. Our team will guide our partners along the often-tricky path to project completion in good time.

We take fresh ideas and put them into as many hands as possible. Using market trends analysis, we determine when and how to strike with the new products that take the world by storm.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.wuhn.org
E-mail:info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/595912/Wuhan-General-Group-Signs-Collaborative-Partnership-LOI-With-Jugular-for-CBD-Functional-Foods

Posted on

Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe

MONTREAL, QC / ACCESSWIRE / June 24, 2020, / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 22nd, 2020, it has entered into a manufacturing, distribution and sales agreement with Cafféluxe for an initial two-year term.

Under the terms of this agreement, Cafféluxe will manufacture Wuhan’s Medspresso™ CBD and Mushroom infused coffee, tea and hot chocolate beverages under GMP (Good Manufacturing Practices) certification. This enables Wuhan to have world-class quality products produced at the highest of safety standards ensuring remarkable customer experience.

The licensing agreement grants Cafféluxe the right to access the Medspresso™ products portfolio, including the use of the trade name, trademarks, logos and art, rights to product formulations, methods and processes. The agreement will facilitate the expansion of the Company’s Medspresso™ brand and position the Company for local (South Africa) and international distribution.

In addition to this, through the sales and distribution agreement, Cafféluxe will sell and distribute Medspresso™ products through their already established network of retailers and distributors locally and globally. Cafféluxe has demonstrated a proven ability to commercialize hot and cold beverages into the African, European, South American and North American marketplace, a key piece of the Wuhan strategic expansion plan.

The Cafféluxe agreement will enable Wuhan to enter legal, international markets around the globe, and to develop a centralized distribution channel for its suite of functional foods and wellness products.

“This partnership is a great first step in developing and executing upon a much larger strategy between Wuhan and the Cafféluxe team. We are looking forward to getting our products on the shelf as soon as the lockdown restrictions are lifted in South Africa and the supply chain constraints have been mitigated,” said Jeff Robinson, Chief Executive Officer of Wuhan General Group.

Michel Sachar, Caffeluxe Commercial Director added: “It has been a real pleasure in getting to know the Wuhan team and planning out a domestic and international launch strategy. Working with the very bright innovative minds at Wuhan has made the relationship such a delight.”

About Cafféluxe

Cafféluxe Food Service offers a full, tailored solution for the manufacturing of single-serve capsules for the retail and business to business sectors. With an in-depth understanding of the nature of coffee and a wealth of experience in the capsule manufacturing field, Cafféluxe expertly manages the process from bean to capsule to cup. This process includes granulating, filling, hermetically sealing, nitrogen flushing, QC testing, packing and branding of the capsules and machines. Cafféluxe Food Serve is able to cater for large and small orders on our machines, this allows for flexibility on various products and customer requirements. Service, compatibility, flexibility, personalization, quality assurance and competitive rates are what make Cafféluxe a leading bespoke capsule manufacturer. Since inception in 2009, Cafféluxe has patented numerous capsule designs, all modified to ensure compatibility, and continues to evolve in a competitive landscape. We provide the capsule with effective, high quality, adaptable products for small- and large-scale private label clients.

We prioritize product innovation and high-quality coffee and capsules, while simultaneously establishing and ensuring lasting relationships with our customers.

Our factory has been granted ISO Standard FSSC 22000 and HACCP Food Safe certification, as well as being FDA compliant and Halaal and Kosher certified. The capsules are subject to a variety of inline and post-production tests. This ensures the quality of the taste and functionality of capsules.

The stringent testing guarantees that Cafféluxe consistently produces capsules of the highest quality in terms of taste and functionality, and provides customers with high quality, premium products.

Profile:https://wuhn.org/wp-content/uploads/2020/06/180525-Caffeluxe-Company-Profile.pdf

Website: https://caffeluxe.com/

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)
Website: www.wuhn.org
E-mail:info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/595012/Wuhan-General-Group-Signs-Manufacturing-Distribution-and-Sales-Agreement-with-Caffluxe

Posted on

Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences

MONTREAL, QC / ACCESSWIRE / June 18, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce a corporate name change and rebranding of the company to M2Bio Sciences, Inc (“M2Bio“). The name change was effective June 17, 2020, with the State of Nevada.

In addition to the new corporate name, the Company ticker symbol on OTCMarket will change to ‘MMBS’ with the approval of Finra. The Company will issue a press release in the near future announcing the date at which the Corporate name and new ticker symbol will take effect.

Along with the name and symbol change, the Company will reveal a new corporate brand identity including a new logo and website. The Company will provide further updates regarding these changes in the near future.

Dr. Anna Morera Leralta, CMO of M2Bio, commented, “Our strategic move marks an important milestone in the Company’s growth. By changing our name, we are branding a strong corporate identity that will exactly personify our company in the eyes of the public and investors. Cannabinoid and psychedelic medicine provide our shareholders with access to a rapidly growing market that is altering the future of healthcare we used to know.”

“The new name M2Bio has been chosen to better reflect the company’s strategic focus on applying Marijuana and Mushrooms into the roots of its research and development of plant-based medicine and drug discovery, and to mark a new chapter in the Company’s growth. We are so deeply committed to developing innovative, better and safer medicines that will truly help treat patients,” said Jeff Robinson, CEO of M2Bio.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)

Website: www.wuhn.org

E-mail: info@wuhn.org

Follow us on Twitter: https://twitter.com/WGG_Company

Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/594322/Wuhan-General-Group-Announces-Name-Change-and-Rebranding-to-M2Bio-Sciences

Posted on

Wuhan General Group Signs Distribution Agreement with Medigrow for International Distribution Rights of Medical Cannabis Products

MONTREAL, QC / ACCESSWIRE / June 10, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the signing of a distribution agreement with Medigrow Africa (“Medigrow”), an African based medical cannabis company with a formal network of legal African cannabis growers producing international medical-grade cannabis products for global distribution.

Under the distribution agreement, Wuhan will receive commercial licenses and rights to Medigrow’s portfolio of medical-grade cannabis and hemp products. In the terms, Wuhan is granted the rights and will be responsible for marketing, distribution, and sales of certain Medigrow proprietary natural hemp and cannabis-based products.

“We see many strategic business opportunities to expand our relationship with Medigrow and this Agreement is the first of many other significant associations going forward with our partner. The Medigrow portfolio of international-grade medical cannabis products is a very tactical addition to our range of products and it really strengthens our commitment to medical cannabis,” said Jeff Robinson, CEO of Wuhan.

“Our product range has been developed using innovative research and specialized formulations in order to deliver valuable health benefits to the consumer. This partnership will reinforce our brands Dr. AnnaRx™ and Medspresso™ as well as raise awareness on the importance of high premium quality medical cannabis ingredients in our products,” added Dr. Anna, CMO of Wuhan.

Medigrow founder and CEO Willem Jonker said; “This partnership is the first of many steps going forward with Jeff Robinson and the Wuhan team. We share a common vision and execution strategies that will enable us to build a very profitable global powerhouse. “

About Medigrow Africa

Medigrow Africa is a formal network of legal African cannabis growers producing international-grade medical cannabis products for global distribution. Medigrow Africa is the the largest collective of African cannabis businesses and it dominates the African medicinal cannabis industry. Medigrow benefits from lower labor, land, and regulatory costs. Also, Medigrow is in the lower quartile of production costs and the upper quartile of profitability globally.

Vision

?Produce European-quality medicinal cannabis with an African cost base.

?Mission

?Our mission is to give as many people in the world access to medicine from the cannabis plant and to benefit as many Africans as possible through the establishment of a medicinal cannabis industry in Africa.

?Strategy

?For our customers: Medigrow Africa brings exceptional African medicinal cannabis products to the global market by combining global best practice and technical resources with traditional local knowledge and Africa’s favorable climate to grow the highest standard of cannabis.

?Sustainability

?Medigrow respects human rights, the rule of law, justice and equality. Therefore, we aim to fully align with the United Nations Agenda 2030 (the Sustainable Development Goals).

?The Global Cannabis market is booming through legalization, declassification, research, entrepreneurship and broader social acceptance. Africa is no different, which is evident in the number of countries that have legalized medicinal cannabis production recently.

?Medigrow envisions Africa as the “centre-court” of future cannabis cultivation. We can see the beginnings of a new legal/formal industry and consequently new means of income, especially in rural areas around Africa. In the longer term, we are convinced that the African Cannabis Industry can help bring steady income to many people that lack work today, assist in building up infrastructure, and blur social stigmas while providing world-class medicinal cannabis to the globe.”

?Our underlying environmental philosophy is continuing to investigate ways to reduce the environmental impact of our operations.

?As part of Medigrow Africa’s intent to maximize the return on every hectare of cannabis, we are particularly mindful of the possible impacts of our operations on the use of natural resources and strive to minimize our impacts through efficient use responsibly and sustainably and through committing ourselves to continuous improvement.

?We strive to comply with all applicable in-country environmental regulations. Furthermore, we are investigating a range of initiatives to preserve ecosystem integrity, protect biodiversity and enhance agricultural sustainability.

?About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)

Website: www.wuhn.org

E-mail:info@wuhn.org

Follow us on Twitter: https://twitter.com/WGG_Company

Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/593336/Wuhan-General-Group-Signs-Distribution-Agreement-with-Medigrow-for-International-Distribution-Rights-of-Medical-Cannabis-Products

Posted on

Wuhan General Group Strengthens Team with New Appointments

MONTREAL, QC / ACCESSWIRE / June 3, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the newly appointed members of the Company.

Mr. Johann McLoughlin hails from the creative hub of Cape Town, South Africa. He joins Wuhan effective immediately as Director of Product Development and Visual Communications and Design. Prior to joining Wuhan, Mr. McLoughlin worked for more than 10 years in custom and design manufacturing of food and cosmetic products. Mr. Mcloughlin will be responsible for the Dr. AnnaRxTM and MedspressoTM brands. ‘’I’m very excited to take on this challenging role at Wuhan. Building out the company brands into global players is my goal.” said Mr. McLoughlin.

Mr. Selah Abrams resides in Los Angeles and has joined Wuhan as Director of Corporate Strategic Partnerships. Mr. Abrams worked for CNN as a Broadcast Production Engineer for 12 years, and prior to that as Director of Media and Technology for CV Sciences, Inc. an early player in the cannabis sector. He is an expert in the field of supply chain management and logistics. In his role, he will lead and oversee Wuhan’s customer partnership teams, responsible for managing strategic accounts and focusing on the development, management and execution of its initiatives to ensure customer success and growth.

Mr. Luka Marjanovic will be assuming his new role as Director of Human Resources and Communications effective immediately. Wuhan thanks him greatly for his dedication and hard work in his prior role as a product developer. In his new appointment, Mr. Marjanovic is tasked to lead by sustaining core values and to build effective teams, to ensure and promote a strong desire to reach the goals set by management. High quality internal and external communication is crucial for people´s inclination to act as ambassadors for their company

Finally, Mr. Rameez Adair of Johannesburg, South Africa has joined the team as Director of Social Media. In his role, Mr. Adair will be responsible for planning, implementing, managing and monitoring Wuhan’s social media strategy in order to increase the Dr. AnnaRxTM and MedspressoTM brand awareness, improve marketing efforts and increase sales.

Wuhan CEO Jeff Robinson stated: ‘‘We are on the verge of some very considerable growth and managing it will be critical. Bringing aboard great talent is key for us at this juncture as it provides us all with a greater depth of expertise from which to draw upon and the tools we need to execute and succeed. I’m beyond ecstatic to see our Wuhan planned journey unfold for our shareholders.”

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
E-mail:info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: https://www.facebook.com/
Follow us on Instagram: https://www.instagram.com/

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/592526/Wuhan-General-Group-Strengthens-Team-with-New-Appointments

Posted on

Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com

AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), announced today that a new audio interview with the Company is now available.

The interview featuring an overview of WUHN’s current news and moves can be heard at https://www.smallcapvoice.com/tag/wuhn/.

Jeff Robinson, CEO of Wuhan, called in to SmallCapVoice.com to go over the business model and markets that his Company operates in. Wuhan is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector.

In addition to the work the Company has been doing in its core markets, Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of cosmetics, coffee, and teas for commercialization in early 2020 within its M2Bio division. M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s.

In the interview Robinson stated, “We are one of only a handful of companies in the world working psilocybin and conducting clinical trials. On the CBD side, once the lockdown, due to the pandemic, ends in South Africa, our products will be on store shelves. That would be the products in the Dr. AnnaRx and Medspresso brands. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.”

Dr. AnnaRx™ is a wholly-owned international trademark of MJ MedTech, used for the branding of its line of by-products and medical research with our high-end Broad-Spectrum Cannabidiol (CBD), is of the highest purity and potency and includes other beneficial cannabinoids, terpenes and molecules, that help promote healthy body and skin care, under the umbrella of Dr. Anna Leralta recommendations.

Wuhan General Group, Inc. is a client of StockVest. StockVest’s team of top Influencers introduces publicly traded companies to a wide audience of investors from around the globe, helping public companies attain maximum market awareness resulting in increased trading volume, a broadened shareholder base and increased share valuations.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Wuhan General Group, Inc.

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at;

Facebook: https://www.facebook.com/SmallCapVoice/

Twitter: https://twitter.com/smallcapvoice

Instagram: https://www.instagram.com/smallcapvoice/

Forward-Looking Statements

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements. For further information contact:

Public Relations

E-mail: info@wuhn.org

For SmallCapVoice.com:

Stuart T. Smith

512-267-2430

info@smallcapvoice.com

Source: SmallCapVoice.com

 

Primary Logo

Posted on

Wuhan to Launch CBD Cosmetics and CBD Infused Coffee in South Africa

Montreal, Nov. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to announce the following corporate updates:

Product Launch

The Company is delighted to announce the launching of its premium CBD product lines in the coming weeks. The launch includes the CBD cosmetics line and the CBD coffee line in pharmacies, convenience stores and hotels across South Africa. The products are branded under the trademarks: DrAnnaRx™ and Medspresso™ respectively.

Initial Creations 

  1.  CBD Advanced Revitalizing Day Cream
  2.  CBD Regenerative Night Cream
  3.  CBD Rejuvenating Skin Oil
  4.  CBD Oil Tinctures
  5.  CBD Infused Tanzanian Peaberry Coffee

Our Premium Pharmaceutical Grade CBD is supplied by Folium Bioscience using their patent-pending cannabinoid extraction technology that offers superior high bioavailability of Broad-Spectrum Phytocannabinoids. This results in a final product that is completely free of THC and ensures our customers receive the highest-quality CBD in the industry.

“Many CBD products introduced to the market are of unverified quality. It has been our mandate to only offer products using pharmaceutical-grade CBD and to deliver only the best for our customers,” commented Jeff Robinson, CEO of Wuhan.

Manufacturing and Distribution in SA

Our CBD creations are manufactured in South Africa by our subsidiary MJ Medtech. Biodelta Nutraceuticals is our distributor in South Africa and surrounding African countries.

Luka Marjanovic commented as Head of Product for the Company: “I’ve been visiting many of the stores that will be carrying our lines. The in-store specialists are very keen to get our product on the shelf. Customer inquiries about CBD based products in the stores are the talk of the town, without anyone to fill the demand gap – until now. Having boots on the ground and such close relationships with our points of sales are of great value and provide us with vital data. For the launch itself, we will conduct significant campaigning, visiting multiple pharmacies per day and conducting doctor training sessions with the personnel and Dr. Anna.”

Online Sales

The DrAnnaRx™ and Medspresso™ lines will be available for purchase online internationally so long as it respects and complies with the countries’ and states’ laws. Both online shops www.drannarx.com and www.medspresso.store will be open for business in December in time for the Holiday season.

Distribution in Canada

In the coming weeks, Wuhan will be applying to Health Canada for its Processing License under the Cannabis Act to allow the sale of cosmetics, topicals, and edibles for medical and legal adult consumer markets.

The Company plans to submit 5 SKUs to Health Canada and plans on submitting more in the coming months as it expands its product lines.

“We are working very hard to create significant value for our shareholders and are definitely going to take advantage of the recent Canadian regulations that went into effect October 17, 2019,” commented Jeff Robinson, CEO of Wuhan.

Delay

Chief Executive Officer Jeff Robinson took a medical leave of absence, during the last quarter. In his absence, company operations were reduced to a minimum until he was fit and healthy to travel back to Cape Town, South Africa. Wuhan is pleased to say that Jeff is in full recovery and back in South Africa with the Team.

Mushrooms

Wuhan has been researching multiple medicinal mushroom types in order to formulate its upcoming range of cosmetics, coffee, and teas for commercialization in early Q1 of 2020 within its M2Bio division.

“We are very excited about the launch in South Africa. We will be selling our products to our first customers in the coming weeks. It’s a huge milestone for the company and its shareholders,” said Jeff Robinson, CEO of Wuhan.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Wuhan General Group, Inc.

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

For further information contact:

Public Relations

E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Primary Logo

Posted on

Wuhan General Group Appoints Distinguished Scientist Dr. Hyder A. Khoja as Chief Scientific Officer

Barcelona, Spain, Aug. 15, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is positioning itself to become a major player in the US$166B medical CBD (cannabidiol) space, as well as the promising psilocybin and medicinal mushroom health sector. The company is pleased to announce that Dr. Hyder A. Khoja (“Dr. Khoja”) is joining Wuhan General Group as Chief Scientific Officer. In his role as CSO, Dr. Khoja will oversee the company’s core research and product development to commercialization.

Dr. Khoja is a trusted and distinguished global leader in cannabinoid & psychedelic medicine. He possesses comprehensive knowledge of the pharmaceutical and dietary supplements industries. His extensive industrial experience spans from advising, innovating and developing cutting-edge projects, to holding various senior-level executive and senior research positions at various biotech companies, universities, and research institutes. His expertise in science and policy domains have led to a distinguished career in scientific research and business development. Dr. Khoja is excited to apply his extensive knowledge with Wuhan to advance botanical-based medicine within the realm of cannabis and mushrooms.

“We extend a warm welcome to Dr. Khoja in this new post,” said Jeff Robinson, CEO of Wuhan. “I have great confidence in Dr. Khoja as an accomplished scientist and recognized leader with a passion for molecular biology and genetic engineering, and with a track record of translating ideas into action, including innovation, commercialization and knowledge mobilization. Dr. Khoja also brings an extensive background in building multi-stakeholder teams and achieving impact on a national and international scale,” Jeff further commented. “This is a huge move forward for Wuhan to bring onboard such remarkable caliber as we move into drug discovery. We will be able to leverage his knowledge and our lab’s cannabis and psychedelics analytics to validate consistent medical-grade compounds for therapeutics. I expect that after we showcase our abilities, we will look for potential licensing opportunities with pharmaceutical companies.”

Dr. Hyder A. Khoja said: “It is the ideal time and opportunity for me to step in and guide Wuhan along the right path and continue my passion for bringing plant genomics and metabolomics for therapeutics to market. As the company is developing its drug discovery and diversifying its technology, I’m eager to leverage my expertise for the goals of the company and its shareholders.”

“We are delighted to have Dr. Khoja on board, with his scientific and industrial expertise, to support our mission of bringing botanical-based medicine to the forefront and lead our scientific and clinical research endeavors,” said Wuhan Chief Medical Officer, Dr. Anna Morera Leralta.

About Dr. Hyder A. Khoja, Ph.D., PAg., eMBA., MSc.

Dr. Khoja is a discovery scientist and serial entrepreneur within the high-tech scientific sector. He received his doctorate (Ph.D.), with honors in “Molecular Biology and Genetic Engineering” from the French Ivy league: INP-ENSAT. He conducted his post-doctoral training from Michigan State University. Soon after, he was appointed as a Research Faculty for Virginia-Tech, University of Wyoming & Texas-Tech University-Health Science Center, respectively. A prolific author, Dr. Khoja has published numerous articles, reviews and books on pharmacological research during his 18-year career in health, pharma and nutraceutical industries on a broader vision to drug discovery for remedial, salubrious and sanative remedies in peer-reviewed journals. In 2011, his work was honored by the United Nations – FAO. Early in 2014, he Co-Founded InMed Pharmaceuticals and directed Botanical Drug Research and Development for their pre-clinical stage novel therapies into the extensive pharmacological application and helped in raising over $90 Million for the venture. He has a command over 12 languages.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx brand. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink: WUHN)

Website: www.wuhn.org

E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Primary Logo

Posted on

Wuhan Announces Strategic Reorganization for Its Operational Advancement in the Medical Marijuana and Psilocybin Mushroom Therapy Markets

BARCELONA, Spain, Aug. 07, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Wuhan General Group, Inc. (OTC PINK: WUHN) (the “Company” and “Wuhan”), is pleased to announce a strategic reorganization that will better position the company to capitalize on the rapidly changing Medical Marijuana and Psilocybin Mushroom industries, while more closely aligning the business with the company’s three primary growth strategies: optimizing the value of the core; increasing health and well-being product lines, and accelerating distribution of new business models.

“Throughout his tenure as CEO, Mr. Kamaneh was instrumental in leading Wuhan in surpassing many milestones, and he has provided sound financial leadership to the Company,” said Jeffrey Robinson, newly appointed CEO. Mr. Kamaneh’s transition as Chief Financial Officer within the company only strengthens managements with his more than fifteen years of experience in finance and various manufacturing industries. Ramy brings a rare combination of expertise leading both public companies and private companies through significant stages of growth. At Wuhan, he will support the company’s next level of expansion by aligning corporate finance with all aspects of the business, from engineering and manufacturing to logistics and operations.

Mr. Robinson further comments: “The transformative joint-venture partnership between Wuhan and Biodelta served as a catalyst for us to re-examine how to best organize the company for increased emphasis on execution and profitable growth. This strategic reorganization focusing on each of our own core strengths, the integration of Wuhan and Biodelta, and long-term growth provide the right structure for us to optimize the value of our businesses today while creating future-oriented opportunities.”

“Mr. Robinson’s appointment and this transition are essential milestones in a succession plan that the board of directors has been working on for the past months,” says Ramy Kamaneh. “Mr. Robinson’s people-focused leadership style, industry expertise, and market understanding will build on the success of the Company. Mr. Robinson is focused on the future and guiding Wuhan in achieving its long-term strategic goals.”

Additionally, Mr. Luka Marjanovic is joining the Wuhan team as Head of Product Development for the MJ MedTech division In South Africa. This new appointment solidifies Wuhan’s core business operations.  Mr. Marjanovic is responsible for the development, implementation, enhancement and support of the Dr. AnnaRx™ and Medspresso™ products, and delivery channels. This includes conceptual stages through research, development, marketing, training, performance tracking and the entire product life cycle in support of Wuhan’s strategic goals and objectives.

Mr. Marjanovic is taking an integrative approach to build solutions and drive product development. “I’m excited to work with the team and to be given the opportunity to apply strategic practices that I’ve gained through my prior experience as we continue to improve our products, processes, and scaling of our operations. The speed, frequency, and timeline of product releases for the Dr. AnnaRx™ line are very impressive,” says Mr. Marjanovic. “We plan to have 30 products in the pipeline by year-end.”

About Luka Marjanovic, BSc., MSc. 

Mr. Marjanovic holds a Bachelor’s in International Business from Denmark and a Master’s in International Management from ESADE Business & Law School. During his undergraduate studies, he founded his own consulting firm, providing services to local businesses in various sectors; as well as working as a research assistant in the field of Big Data. Prior to his education, he served in the Danish Royal Army as Second Sergeant, leading and managing a group of men, under extreme pressures and conditions. Luka has spent significant time abroad, living and working in six different countries, and is now responsible for designing business models and go-to-market strategies for Dr. AnnaRx™ and Medspresso™ products.

About Wuhan General Group, Inc.

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for new Psilocybin therapies that will help patients who suffer from mental illness, Alzheimer and Parkinson disease. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board under the trading symbol “WUHN”.

For further information:
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
Public Relations E-mail: info@wuhn.org

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the 

meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

Primary Logo